Adlai Nortye Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

123

Market Cap

392.25M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	45.73M	-	-
Dec 31, 2020	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Puma Biotechnology	212.00M
Cellectis	82.55M
XOMA Royalty	47.11M
Neurogene	925.00K
Abeona Therapeutics	400.00K
Avalo Therapeutics	192.00K

Revenue Rankings

ANL News

4 weeks ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
3 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
1 year ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
1 year ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
2 years ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire
2 years ago - Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award - GlobeNewsWire
2 years ago - Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles - Seeking Alpha

More News